We also assessed expression of activation-responsive immune genes TNF, IL21, IL10, IL13, and CFS2 in the ICB melanoma dataset, and found that IFNG, TNF, and interleukins IL21 and IL10 seemed to increase upon treatment in responders (Supplementary Figure S3C), even though they were not differentially expressed. The gene discussed is IL21; the disease is melanoma.